Working… Menu

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03600805
Recruitment Status : Terminated (Protracted recruitment timeline exacerbated by COVID-19 pandemic)
First Posted : July 26, 2018
Last Update Posted : December 28, 2020
Regeneron Pharmaceuticals
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : November 24, 2020
Actual Study Completion Date : November 24, 2020